<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01924728</url>
  </required_header>
  <id_info>
    <org_study_id>QRSPelvicenter</org_study_id>
    <nct_id>NCT01924728</nct_id>
  </id_info>
  <brief_title>Efficacy of Magnetic Stimulation for Stress Urinary Incontinence</brief_title>
  <official_title>A Randomized, Double-blind, Placebo Controlled Clinical Trial to Investigate the Effects of Transpelvic Magnetic Stimulation (Using QRS®-1010 PelviCenter) in Patients With Stress Urinary Incontinence.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>QRS Asia Sdn Bhd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Science Malaysia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Island Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Penang Adventist Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>QRS Asia Sdn Bhd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to investigate the effects of QRS®-1010 PelviCenter in female
      patients with stress urinary incontinence.

      Based on the available data on magnetic stimulation, the investigators hypothesize that
      magnetic stimulation via QRS®-1010 PelviCenter will reduce the number and amount of urinary
      leakage upon exertion as well as improve patients' quality of life.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 120 female patients will be randomly assigned into two treatment groups (active
      arm and sham arm) in a 1:1 ratio. The standard QRS®-1010 PelviCenter treatment plan involves
      16 sessions of 20 minutes each. Each subject will attend 2 sessions per week (total 16
      sessions).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in International consultation on incontinence questionnaire for urinary incontinence-short form (ICIQ-UI SF)</measure>
    <time_frame>Baseline, Week 4, 8. Follow-up at 3-,6- and 12-months post treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Incontinence Episode Frequency (IEF)</measure>
    <time_frame>Baseline, Week 4, 8. Follow-up at 3-,6- and 12-months post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 1-hour exercise (stress) pad test</measure>
    <time_frame>Baseline, Week 4, 8. Follow-up at 3-,6- and 12-months post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Patient Global Impression of Improvement (PGI-I)</measure>
    <time_frame>Week 4, 8. Follow-up at 3-,6- and 12-months post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in International consultation on incontinence questionnaire-Lower Urinary Tract Symptoms Quality of Life (ICIQ-LUTSqol)</measure>
    <time_frame>Baseline, Week 4, 8. Follow-up at 3-,6- and 12-months post treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Stress Urinary Incontinence</condition>
  <arm_group>
    <arm_group_label>Magnetic stimulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active magnetic stimulation delivered to the pelvic floor muscles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham magnetic stimulation</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham magnetic stimulation delivered to the pelvic floor muscles</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Magnetic stimulation</intervention_name>
    <description>50Hz active magnetic stimulation (coil position 100%) delivered to the pelvic floor muscles</description>
    <arm_group_label>Magnetic stimulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham magnetic stimulation</intervention_name>
    <description>50Hz sham magnetic stimulation (coil position 0%) delivered to the pelvic floor muscles</description>
    <arm_group_label>Sham magnetic stimulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female aged at least 21 years old

          -  Demonstration of stress urinary incontinence by vaginal examination with half full
             bladder (200 to 250ml)

          -  ICIQ UI SF score ≥ 6 points

          -  Able and agree to carry out one hour pad test

        Exclusion Criteria:

          -  Acute severe infections

          -  Urinary tract infections and hematuria, active vaginal lesions or infections

          -  Pelvic organ prolapse stage III and IV, severe urethral sphincter weakness/defect,
             suspected fistula

          -  Severe cardiac arrhythmia

          -  Cardiac pacemaker or other implanted metallic devices

          -  History of pelvic irradiation

          -  Pregnant, or actively trying to conceive.

          -  Neurologic conditions such as epilepsy, Parkinson disease, multiple sclerosis

          -  Patient who has been treated with electromagnetic stimulation

          -  Concurrent medications with alpha-adrenergic antagonists (e.g. terazosin, tamsulosin,
             doxazosin), diuretics, serotonin/norepinephrine reuptake inhibitors (SNRIs) or any
             other medications known to worsen incontinence.

          -  Post void residual volume of ≥ 200ml

          -  Random blood sugar &gt;10 mmol/L

          -  Patient who had pelvic or gynaecological surgery for less than three weeks

          -  Patient scheduled for pelvic or gynaecological surgery in the next eight weeks
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Liong Men Long, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Island Hospital, Penang</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Island Hospital</name>
      <address>
        <city>Penang</city>
        <zip>10450</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Malaysia</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 14, 2013</study_first_submitted>
  <study_first_submitted_qc>August 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2013</study_first_posted>
  <last_update_submitted>February 19, 2016</last_update_submitted>
  <last_update_submitted_qc>February 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>QRS Asia Sdn Bhd</investigator_affiliation>
    <investigator_full_name>Lim Renly</investigator_full_name>
    <investigator_title>M. Pharm</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
    <mesh_term>Urinary Incontinence, Stress</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

